Data across EXPLORER-HCM, MAVA-LTE and PIONEER-OLE add to the growing body of evidence from the CAMZYOS® (mavacamten) development program, reinforcing the therapeutic value and benefit to patients
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research supporting the company’s cardiovascular franchise at the American College of Cardiology (ACC) Annual Scientific Session & Expo together with the World Congress of Cardiology (WCC), taking place in-person and virtually March 4-6, 2023. Findings from clinical studies will be featured, including several moderated poster presentations from the CAMZYOS® (mavacamten) development program showcasing data across various subgroups of patients with obstructive hypertrophic cardiomyopathy (HCM). During the meeting, the Bristol Myers Squibb-Pfizer Alliance will also present results characterizing the healthcare provider perspective on consumer wearables for atrial fibrillation detection.
“At this year’s ACC, we are proud to showcase both short and long-term data that continues to exemplify our mission of developing and delivering medicines that make a real difference in the lives of cardiovascular patients,” said Roland Chen, MD, senior vice president and head of cardiovascular development, Global Drug Development at Bristol Myers Squibb. “We look forward to presenting CAMZYOS 156-week data, the longest study of any myosin inhibitor, and additional analyses across a variety of patient subgroups, reinforcing its therapeutic value and benefit to patients.”
Key presentations include:
Summary of Presentations
Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at ACC.23/WCC include:
Abstract Title | Primary Author | Type/# | Session Title | Time (CT) |
Sunday, March 5, 2023 | ||||
Consumer wearables for atrial fibrillation detection: Results of a survey to characterize the healthcare provider perspective* | Simonson, J | Poster – 1464-036 | 1464 - Spotlight on Special Topics: Innovation, Digital Health, and Technology 8 | 9:45 AM – 10:30 AM |
The effect of mavacamten treatment for symptomatic, obstructive hypertrophic cardiomyopathy in patients with or without hypertension: Analysis of the EXPLORER-HCM trial | Wang, A | Moderated Poster – 1042-09 | 1042 - Bulking Up: New Research in Hypertrophic Cardiomyopathy | 10:00 AM – 10:10 AM |
96-week cardiac magnetic resonance (CMR) results of treatment with mavacamten from the EXPLORER cohort of the MAVA-long-term extension (LTE) study in patients (pts) with obstructive hypertrophic cardiomyopathy (HCM) | Saberi, S | Moderated Poster – 1042-11 | 1042 - Bulking Up: New Research in Hypertrophic Cardiomyopathy | 10:15 AM – 10:25 AM |
The effect of mavacamten treatment for symptomatic, obstructive hypertrophic cardiomyopathy in patients of older age and longer duration of diagnosis: Analysis of the EXPLORER-HCM trial | Wang, A | Moderated Poster – 1042-13 | 1042 - Bulking Up: New Research in Hypertrophic Cardiomyopathy | 10:30 AM – 10:40 AM |
Women in EXPLORER-HCM had more severe heart failure at baseline but similar, or greater, response to mavacamten | Cresci, S | Moderated Poster – 1066-03 | 1066 - The Latest Hype In Hypertrophic Cardiomyopathy | 2:30 PM – 2:40 PM |
Long-term safety and efficacy of mavacamten in patients (pts) with symptomatic obstructive hypertrophic cardiomyopathy (HCM): Updated results from the PIONEER-OLE study | Masri, A | Moderated Poster – 1066-07 | 1066- The Latest Hype In Hypertrophic Cardiomyopathy | 3:00 PM – 3:10 PM |
Obstructive HCM patients in EXPLORER-HCM with high left ventricular filling pressures had more severe heart failure but similar or greater response to mavacamten | Cresci, S | Moderated Poster – 1066-09 | 1066- The Latest Hype In Hypertrophic Cardiomyopathy | 3:15 PM – 3:25 PM |
*Sponsored by the Bristol Myers Squibb-Pfizer Alliance
About CAMZYOS (mavacamten)
CAMZYOS (mavacamten) is the first and only cardiac myosin inhibitor approved in the U.S., indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. It has also received regulatory approvals in Australia, Canada, and Brazil. CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In HCM patients, myosin inhibition with CAMZYOS reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HEART FAILURE
CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.
Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF